Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer’s IBRANCE Wins Accelerated Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Pfizer’s IBRANCE Wins Accelerated Approval

Phase II trial shows progression-free survival in beast cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer was granted accelerated approval from the FDA for IBRANCE (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent the confirmatory Phase III trial, PALOMA-2, which is fully enrolled.

IBRANCE was approved under the FDA’s Breakthrough Therapy designation and Priority Review programs based on results of the Phase II PALOMA-1 trial.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics